Business Wire - August 5, 2002
Resurgex was officially launched and qualified for Medicaid reimbursement in Connecticut and New Jersey in September 2001. It was launched in Nevada in April 2002.
Resurgex is a multi-component nutritional supplement designed to assist in maintaining lean muscle, decreasing oxidative stress, supporting immune function and increasing energy. As an adjunct to medical care, Millennium believes that Resurgex may have clinical benefit for immuno-compromised conditions such as HIV/AIDS, Hepatitis-C and Cancer.
"We are very encouraged with the overwhelming response that we have received from physicians regarding Resurgex. In less than a year, we have made significant progress in our initial target launch of three states," said Jerry Swon, CEO & President of Millennium Biotechnologies. Mr. Swon added, "We are now gearing up for our expansion program into other states."
Millennium Biotechnologies, Inc., a research-based nutraceutical company, is a pioneer in the emerging field of nutritional science. The Company is developing innovative nutritional supplements for patients and healthcare providers that serve as important adjuncts to current medical treatments and therapies.
This news release contains forward-looking statements that are based upon management's beliefs as well as on assumptions made by and data currently available to management. This information which has been, or in the future may be, included in reliance on the "safe harbor" provisions on the Private Securities Litigation Reform Act of 1995, is subject to a number of risks and uncertainties, including but not limited to uncertainty as to market acceptance of Resurgex and the factors identified in the Company's 10-KSB and other documents filed with the Securities and Exchange Commission. Actual results may differ materially from those anticipated in such forward-looking statements even if experience or future changes make it clear that any projected results expressed or implied therein may not be realized. The Company undertakes no obligation to update or revise any forward-looking statements to reflect subsequent events or circumstances.
CONTACT: Millennium Biotechnologies Jerry Swon, 908/630-8700 or Investor Contacts: Lippert/Heilshorn & Associates, Inc. Kim Golodetz/Ethan Denkensohn, 212/838-3777 Bruce Voss, 310/691-7100
SOURCE: Millennium Biotechnologies
020805
BW020802
Copyright © 2002 - Business Wire. All rights reserved. Reproduced with permission. Reproduction of this article (other than one copy for personal reference) must be cleared through the Business Wire, Permissions Desk, Business Wire, 1185 Avenue of the Americas, 3rd Floor, New York, NY 10036; Tel: (212) 575-8822; FAX: (212) 575-1854. http://www.businesswire.com.
AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Broadway Cares/Equity Fights AIDS, Elton John AIDS Foundation, the National Library of Medicine, Pacific Life Foundation and donations from users like you.
Always watch for outdated information. This article first appeared in 2002. This material is designed to support, not replace, the relationship that exists between you and your doctor.
AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.
Copyright ©1980, 2002. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .